Drug Profile


Alternative Names: Resolvine; Resolvine ER

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KATO Pharmaceuticals
  • Developer KATO Pharmaceuticals; Ophthalmic Consultants of Boston
  • Class Anti-inflammatories; Eye disorder therapies; Omega 3 fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Retinal disorders
  • Preclinical Diabetic retinopathy

Most Recent Events

  • 10 Oct 2016 Kato Pharmaceuticals plans a phase II trial in Diabetic retinopathy in USA
  • 07 Oct 2016 Resolvine ER licensed to Lee's Pharmaceuticals in China, Hong Kong, Macau, Taiwan and South East Asia
  • 07 Oct 2016 Preclinical trials in Diabetic retinopathy in USA (Intravitreous, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top